Recent progress in the treatment of locally advanced head and neck squamous cell carcinomas

Purpose: Concurrent chemoradiotherapy (CRT) has become the standard of care (SOC) for locally advanced (LA) head and neck squamous cell carcinomas (HNSCC) since the French meta-analysis MACH-NC. This review synthesizes recent clinical research progress in LA-HNSCC, focusing on findings from Institut Gustave-Roussy and the French Head and Neck Oncology and Radiotherapy Group (GORTEC). Recent findings: Recent phase 3 trials have explored modifications to CRT protocols with mixed results. The GORTEC 99-02 phase 3 trial demonstrated no additional benefit from combining accelerated radiotherapy (RT) with CRT. Similarly, induction chemotherapy with taxane-platinum-5FU (TPF) followed by RT with cetuximab did not improve outcomes compared to CRT alone in patients with LA-HNSCC (>N2a) in the GORTEC 2007-02 trial. However, in patients with N0-N2a HNSCC, concurrent chemotherapy plus cetuximab-RT outperformed cetuximab-RT in the GORTEC 2007-01 phase 3 trial. Another targeted therapy, the IAP antagonist xevinapant, combined with cisplatin-RT, exhibited promising outcomes in the randomized phase 2 trial Debio1143-201 (GORTEC 2015-03). However, the subsequent phase 3 Trilynx trial failed to confirm xevinapant’s benefit when added to CRT in LA-HNSCC. Immunotherapy integration has been extensively studied. Since 2015, several phase 2/3 trials, including GORTEC 2015-01 (PembroRad), GORTEC 2017-01 (REACH), KEYNOTE-412, and GORTEC 2018-02 (REWRITe), have evaluated immune checkpoint inhibitors (ICIs) combined with RT/CRT in cisplatin-eligible and ineligible patients with unresectable LA-HNSCC. These trials found no clear benefit from concurrent or adjuvant ICI use alongside RT/CRT. In contrast, the KEYNOTE-689 trial, which investigated perioperative pembrolizumab with standard surgery and postoperative RT/CRT for resectable LA-HNSCC, and the GORTEC 2018-01 (NIVOPOSTOP) phase 3 trial, which assessed post-operative nivolumab with cisplatin-RT in resected high-risk LA-HNSCC, have shown preliminary encouraging results with full data expected soon. Summary: Platinum-based CRT remains the SOC for LA-HNSCC. Emerging evidence suggests that perioperative pembrolizumab or postoperative nivolumab may redefine the SOC for resectable or resected HNSCC. Novel combinations, including molecular targeted therapies and ICIs with RT/CRT, require further investigation to establish their efficacy.

• Publication year

  2025

• Venue

  Visualized Cancer Medicine

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1051/vcm/2025009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• 852MO REWRITE–GORTEC 2018-02: Radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck

  2024cited by this paper
• 854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial

  2024cited by this paper
• SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responses.

  2023cited by this paper
• Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.

  2023cited by this paper
• Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck: a plain language summary.

  2023cited by this paper
• LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

  2022cited by this paper
• Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).

  2022cited by this paper
• Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.

  2022cited by this paper
• 653O Neoadjuvant nivolumab (N) before chemoradiation (CRT) in high-risk HPV driven oropharynx cancer (OPC) - IMMUNEBOOST-HPV: A multicenter randomized phase II trial

  2022cited by this paper
• LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

  2021cited by this paper
• Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

  2021cited by this paper
• Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).

  2020cited by this paper
• Concurrent cisplatin and Dose escalation with Intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.

  2020cited by this paper
• 914MO Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial

  2020cited by this paper
• DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death

  2018cited by this paper
• Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.

  2018cited by this paper
• Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.

  2017cited by this paper
• Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients.

  2017cited by this paper
• Can immunostimulatory agents enhance the abscopal effect of radiotherapy?

  2016cited by this paper
• Concurrent Chemoradiation Therapy Versus Acceleration of Radiation Therapy With or Without Concurrent Chemotherapy in Locally Advanced Head and Neck Carcinoma (GORTEC 99-02): 7-Year Survival Data From a Phase 3 Randomized Trial and Prognostic Factors

  2016cited by this paper
• The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.

  2015cited by this paper
• Comprehensive genomic characterization of head and neck squamous cell carcinomas

  2015cited by this paper
• Targeting IAP proteins for therapeutic intervention in cancer

  2012cited by this paper
• A phase I trial combining oral cisplatin (CP Ethypharm) with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma.

  2011cited by this paper
• Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent.

  2011cited by this paper
• Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial.

  2011cited by this paper
• Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

  2009cited by this paper
• Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.

  2009cited by this paper
• Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection.

  2009cited by this paper
• Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma.

  1999cited by this paper

• Preliminary study of cyto-impedance: Molecular profiling of functional impedance in motility-promoting treatment of normal cells

  2026cites this paper